Balanced news tone
News Sentiment
UNCY sentiment intelligence
Unicycive Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
44
Balanced news tone
61 relevant articles
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-9.1% over one week, -28.1% over four weeks, trend inactive, and below fair value.
Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
81/100 classification
One-week reaction
-9.1%
Price reacting lower
Trend fit
Trend inactive
-28.1% over four weeks
Fair value
-24.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
33
Negative
17
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
The Globe and Mail
Direct company coverage
Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group
Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Ben
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 15 Jul 2026 08:42
- Source
- The Globe and Mail
Stocktwits
Direct company coverage
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval
Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% as retail investors speculated on the potential FDA approval of its drug, Oxylanthanum carbonate (OLC). The company resubmitted its application for OLC, a treatment for hyperphosphatemia in chronic kidney disease patients on d
- Tone
- Positive 73/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 14:42
- Source
- Stocktwits
GlobeNewswire
Direct company coverage
UNCY: Unicycive Therapeutics Investors with Losses Should
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 13 Jul 2026 18:05
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application due to third-party manufacturing deficiencies. Investors who have lost money in Uni
- Tone
- Negative 25/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 17:39
- Source
- GlobeNewswire
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
GlobeNewswire
Direct company coverage
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
Kirby McInerney LLP is investigating Unicycive Therapeutics, Inc. regarding potential violations of federal securities laws after the FDA issued a second Complete Response Letter for the company's kidney disease therapy, causing a significant stock price drop. Investors who purch
- Tone
- Negative 27/100
- Event
- Market update
- Published
- 10 Jul 2026 23:41
- Source
- GlobeNewswire
Simply Wall Street
Direct company coverage
Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis
Unicycive Therapeutics (Nasdaq:UNCY) is a clinical-stage biotechnology company focused on kidney disease therapies. The company has recently faced setbacks with its oxylanthanum carbonate drug application due to manufacturing deficiencies, leading to significant stock price drops
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 09 Jul 2026 22:41
- Source
- Simply Wall Street
Stock Titan
Direct company coverage
Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY)
A Schedule 13G/A filing reveals that Millennium-affiliated entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, beneficially own 271,456 shares (1.0%) of Unicycive Therapeutics (UNCY). Separately, Integrated Core Strategies (US)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 22:11
- Source
- Stock Titan
The AI Journal
Direct company coverage
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announced an investigation into Unicycive Therapeutics, Inc. (UNCY) for possible federal securities law violations. This follows a significant stock price drop after Unicycive disclosed a second Complete Response Letter from the FDA for its kidney
- Tone
- Negative 27/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 22:44
- Source
- The AI Journal
TradingView
Direct company coverage
Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY
The article focuses on the "Price to book forward" metric for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It appears to be a financial data snippet from TradingView, indicating a specific financial ratio without providing extensive details or analysis. The content primarily list
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 08:41
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY
The article discusses the forward price-to-earnings ratio for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It provides financial data and links to various tools and resources available on the TradingView platform for analyzing the stock.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 04:40
- Source
- TradingView
Finviz
Direct company coverage
UNCY - Unicycive Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filing information for Unicycive Therapeutics Inc (UNCY) from Finviz. It includes a comprehensive overview of the company's financial data, stock performance metrics, insider ownership, institutional ownership, and analyst ratings. Key financi
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 04 Jul 2026 21:41
- Source
- Finviz
Finviz
Direct company coverage
UNCY - Unicycive Therapeutics Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Unicycive Therapeutics Inc (UNCY). It includes key financial metrics such as market capitalization, income, sales, EPS, and various ratios, alongside performance indicators like 52-week high/low, volatility, and
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 20:41
- Source
- Finviz
simplywall.st
Direct company coverage
Why Unicycive Therapeutics (UNCY) Is Down 19.6% After FDA CRL Over Third-Party Manufacturing Issues And What's Next
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 17:34
- Source
- simplywall.st
Finviz
Direct company coverage
UNCY - Unicycive Therapeutics Inc Short Interest
This article provides a detailed financial overview of Unicycive Therapeutics Inc (UNCY), focusing on its short interest. It covers key financial metrics, stock performance data, insider and institutional ownership, and various ratios, painting a comprehensive picture of the comp
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 03:39
- Source
- Finviz
Carroll County Mirror-Democrat
Direct company coverage
Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of its stockholders after the company announced a second Complete Response Letter from the FDA for its New Drug Application. This news led to a nearly 39% decline in Unicycive's sha
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 02 Jul 2026 17:40
- Source
- Carroll County Mirror-Democrat
TradingView
Direct company coverage
Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026
Unicycive Therapeutics reported a preliminary cash balance of approximately $61.4 million as of June 30, 2026, indicating available liquidity. These stated results are preliminary, prepared by management, and have not been audited or reviewed by independent accountants. The compa
- Tone
- Positive 63/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 14:40
- Source
- TradingView
Stock Titan
Direct company coverage
Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update
Unicycive Therapeutics, Inc. reported a preliminary, unaudited cash balance of approximately $61.4 million as of June 30, 2026, as part of its second-quarter results. The company disclosed this information via an 8-K filing under Item 8.01, indicating a material event deemed impo
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 14:40
- Source
- Stock Titan
Market source
Direct company coverage
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
Unicycive Therapeutics (UNCY) shares dropped 33.1% after the FDA issued a Complete Response Letter for its oxylanthanum carbonate NDA, citing third-party manufacturing deficiencies. The letter raised no concerns about clinical efficacy or safety, but instead highlighted unresolve
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 02 Jul 2026 04:13
- Source
- Market source
Business Wire
Direct company coverage
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP is investigating potential securities fraud claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation follows a significant 39% stock price drop after Unicycive announced a second Complete Response Letter from the FDA regarding its kidney
- Tone
- Negative 29/100
- Event
- Regulatory and legal
- Published
- 01 Jul 2026 22:39
- Source
- Business Wire
Stock Titan
Direct company coverage
[144] Unicycive Therapeutics, Inc. SEC Filing
This article reports on Unicycive Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold including details of acquisition and payment, and confirms no securities
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 21:39
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for
Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application, citing unresolved third-party manufacturing deficiencies. This news led to a decli
- Tone
- Negative 28/100
- Event
- Market update
- Published
- 01 Jul 2026 15:10
- Source
- GlobeNewswire
Sahm
Direct company coverage
Why Is Unicycive Therapeutics Stock Falling Tuesday?
Unicycive Therapeutics' stock fell over 46% after the FDA issued a Complete Response Letter (CRL) for its kidney disease drug application, citing third-party manufacturing deficiencies. This is the second time the FDA has raised these concerns, despite the company's belief that t
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 01 Jul 2026 13:39
- Source
- Sahm
Reuters
Direct company coverage
Unicycive Therapeutics Inc
Unicycive Therapeutics announced that the U.S. FDA has declined to approve its kidney disease drug for elevated phosphate levels in chronic kidney disease patients on dialysis. The FDA cited deficiencies at a third-party manufacturing facility as the reason for the non-approval.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 08:40
- Source
- Reuters
EIN Presswire
Direct company coverage
Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA
Unicycive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate (OLC) NDA, citing deficiencies at a third-party manufacturing vendor, not related to clinical efficacy or safety. The company is actively discussing labeling
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 01 Jul 2026 04:17
- Source
- EIN Presswire
Stocktwits
Direct company coverage
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics (UNCY) experienced its worst day in over a year after the FDA again refused to approve its drug oxylanthanum carbonate due to third-party manufacturing issues. Despite the setback and potential 5-12 month delay, B. Riley and H.C. Wainwright maintained their
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 17:34
- Source
- Stocktwits
GlobeNewswire
Direct company coverage
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) following a decline in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's OLC NDA due to unresolved third-party manufacturing deficienci
- Tone
- Negative 13/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 16:41
- Source
- GlobeNewswire
grafa.com
Direct company coverage
Unicycive gets FDA CRL for OLC kidney drug application
Unicycive Therapeutics (NASDAQ:UNCY) received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate New Drug Application. The CRL cited third-party manufacturing deficiencies as the reason, with no issues raised regarding the drug's safety or efficacy. The
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 30 Jun 2026 14:41
- Source
- grafa.com
The Business Journals
Direct company coverage
FDA rejects drug again for same manufacturing issue, chopping stock in half
The FDA has rejected Unicycive's kidney disease drug a second time, specifically citing an ongoing manufacturing issue with its Indian supplier. This decision caused the company's stock to drop by half. Despite the manufacturer supplying drugs for other U.S. companies, the FDA ha
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 30 Jun 2026 13:41
- Source
- The Business Journals
StocksToTrade
Direct company coverage
UNCY Extends ATM Offering As Dilution Fears Hit The Chart
Unicycive Therapeutics Inc. (NASDAQ: UNCY) shares have fallen by 46.04% due to investor concerns over clinical and financing uncertainties. The company filed a $150 million mixed securities shelf and expanded its at-the-market (ATM) equity program with Guggenheim Securities from
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 30 Jun 2026 13:41
- Source
- StocksToTrade